Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + Pucotenlimab + Platinum Induction Followed by Chemoradiotherapy for Locally Advanced Unresectable NSCLC
NCT07882940Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2026
- Primary completion
- Oct 2029
01
Overview
A Phase 2 trial of becotatug vedotin, pucotenlimab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07882940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07882940.